Radiofrequency Ablation Provides Rapid and Durable Pain Relief for the Palliative Treatment of Lytic Bone Metastases Independent of Radiation Therapy: Final Results from the OsteoCool Tumor Ablation Post-Market Study

• Published in: Cardiovascular and interventional radiology 2023-05, Vol.46 (5), p.600-609
• Main Authors: Levy, Jason, David, Elizabeth, Hopkins, Thomas, Morris, Jonathan, Tran, Nam D., Farid, Hamed, Massari, Francesco, O’Connell, William G., Vogel, Alexander, Gangi, Afshin, Sunenshine, Peter, Dixon, Robert, Von der Höh, Nicolas, Bagla, Sandeep
• Format: Article
• Language: English
• Subjects: Ablation; Adverse events; Bone Neoplasms - radiotherapy; Bone Neoplasms - secondary; Cardiology; Catheter Ablation - methods; Chemotherapy; Clinical Investigation; Humans; Imaging; Interference; Medicine; Medicine & Public Health; Metastases; Metastasis; Non-Vascular Interventions; Nuclear Medicine; Pain; Pain - surgery; Palliation; Palliative Care - methods; Prospective Studies; Quality of Life; Radiation; Radiation therapy; Radio frequency; Radiofrequency ablation; Radiofrequency Ablation - methods; Radiology; Statistical analysis; Treatment Outcome; Tumors; Ultrasound
• ISSN: 0174-1551; 1432-086X
• DOI: 10.1007/s00270-023-03417-x

Purpose The OsteoCool Tumor Ablation Post-Market Study (OPuS One) was a prospective, multi-national, single-arm study to investigate safety and effectiveness of radiofrequency ablation (RFA) for palliation of painful lytic bone metastases with 12 months of follow-up. RFA has demonstrated effective palliation of osseous metastases in small clinical studies with short-term follow-up; however, a long-term assessment with robust subject numbers is lacking. Materials and Methods Prospective assessments were conducted at Baseline, 3 days, 1 week, and 1, 3, 6, and 12-months. Pain and quality of life were measured prior to RFA and postoperatively using the Brief Pain Inventory, European Quality of Life—5 Dimension, and European Organization for Research and Treatment of Cancer Care Quality of Life Questionnaire for palliative care. Radiation, chemotherapy and opioid usage, and related adverse events were collected. Results 206 subjects were treated with RFA at 15 institutions in OPuS One. Worst pain, average pain, pain interference and quality of life significantly improved at all visits starting 3 days post-RFA and sustained to 12 months ( P